These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 1516279)

  • 1. Clearance of 131I by hemodialysis.
    Culpepper RM; Hirsch JI; Fratkin MJ
    Clin Nephrol; 1992 Aug; 38(2):110-4. PubMed ID: 1516279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iodine-131 pharmacokinetics in patients on hemodialysis for end stage renal disease: clinical implications.
    Courbon F; Caselles O; Zerdoud S; Duthil P; Regis H; Berry I; Caron P
    Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):363-70. PubMed ID: 17043635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiation safety protocol for high dose 131I therapy of thyroid carcinoma in patients on hemodialysis for chronic renal failure.
    Modarresifar H; Almodovar S; Bass WB; Ojha B
    Health Phys; 2007 Feb; 92(2 Suppl):S45-9. PubMed ID: 17228187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Administration of additional inactive iodide during radioiodine therapy for Graves' disease: who might benefit?
    Dietlein M; Moka D; Reinholz U; Schmidt M; Schomäcker K; Schicha H; Wellner U
    Nuklearmedizin; 2007; 46(3):77-84. PubMed ID: 17549318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of dialysis on 131I kinetics and dosimetry in thyroid cancer patients--a pharmacokinetic model.
    Pahlka RB; Sonnad JR
    Health Phys; 2006 Sep; 91(3):227-37. PubMed ID: 16891898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemodialysis clearance of ethosuximide in patients with chronic renal disease.
    Marbury TC; Lee CS; Perchalski RJ; Wilder BJ
    Am J Hosp Pharm; 1981 Nov; 38(11):1757-60. PubMed ID: 7304633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased binding of beta-2-microglobulin to blood cells in dialysis patients treated with high-flux dialyzers compared with low-flux membranes contributed to reduced beta-2-microglobulin concentrations. Results of a cross-over study.
    Traut M; Haufe CC; Eismann U; Deppisch RM; Stein G; Wolf G
    Blood Purif; 2007; 25(5-6):432-40. PubMed ID: 17957097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemodialysis in patients requiring 131I treatment for thyroid carcinoma.
    Fofi C; Festuccia F; Barberi S; Apponi F; Chiacchiararelli L; Scopinaro F; Punzo G; Menè P
    Int J Artif Organs; 2013 Jun; 36(6):439-43. PubMed ID: 23653300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Experience with a high-dose therapy concept in metastatic differentiated thyroid cancer].
    Grünwald F; Ruhlmann J; Ammari B; Knopp R; Hotze A; Biersack HJ
    Nuklearmedizin; 1988 Dec; 27(6):266-71. PubMed ID: 3217257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemodialysis clearance of total and unbound lidocaine.
    Jacobi J; McGory RW; McCoy H; Matzke GR
    Clin Pharm; 1983; 2(1):54-7. PubMed ID: 6883930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma.
    Schlumberger M; Challeton C; De Vathaire F; Travagli JP; Gardet P; Lumbroso JD; Francese C; Fontaine F; Ricard M; Parmentier C
    J Nucl Med; 1996 Apr; 37(4):598-605. PubMed ID: 8691248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Busulfan clearance in renal failure and hemodialysis.
    Ullery LL; Gibbs JP; Ames GW; Senecal FM; Slattery JT
    Bone Marrow Transplant; 2000 Jan; 25(2):201-3. PubMed ID: 10673681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Necessity to administer 131I in a patient with papillary thyroid carcinoma undergoing chronic hemodialysis].
    Novik V; González R; Díaz M; Vega J
    Rev Med Chil; 1998 Jul; 126(7):874-5. PubMed ID: 9830782
    [No Abstract]   [Full Text] [Related]  

  • 15. Disposition of didanosine in HIV-seropositive patients with normal renal function or chronic renal failure: influence of hemodialysis and continuous ambulatory peritoneal dialysis.
    Knupp CA; Hak LJ; Coakley DF; Falk RJ; Wagner BE; Raasch RH; van der Horst CM; Kaul S; Barbhaiya RH; Dukes GE
    Clin Pharmacol Ther; 1996 Nov; 60(5):535-42. PubMed ID: 8941026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical and analytical changes in hemodialysis without acetate].
    Coll E; Pérez-García R; Rodríguez-Benítez P; Ortega M; Martínez Miguel P; Jofré R; López-Gómez JM
    Nefrologia; 2007; 27(6):742-8. PubMed ID: 18336105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dosing of gentamicin in patients with end-stage renal disease receiving hemodialysis.
    Teigen MM; Duffull S; Dang L; Johnson DW
    J Clin Pharmacol; 2006 Nov; 46(11):1259-67. PubMed ID: 17050791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic 131I in outpatients: a simplified method conforming to the Code of Federal Regulations, title 10, part 35.75.
    Coover LR; Silberstein EB; Kuhn PJ; Graves MW
    J Nucl Med; 2000 Nov; 41(11):1868-75. PubMed ID: 11079497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Factors which influence phosphorus removal in hemodialysis].
    Gallar P; Ortiz M; Ortega O; Rodríguez I; Seijas V; Carreño A; Oliet A; Vigil A
    Nefrologia; 2007; 27(1):46-52. PubMed ID: 17402879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiation safety implications of 131I treatment in a patient with Grave's disease undergoing home hemodialysis.
    Simpson JB; Godwin GA
    Health Phys; 2006 Dec; 91(6):570-3. PubMed ID: 17099400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.